Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-BLP25 plus best supportive care vs placebo in unresectable stage III non-small cell lung cancer
CTR20132488Phase 3Suspended
- Sponsor
- Merck KGaA
- Start
- Oct 2014
- Modality
- Vaccines & Immunotherapeutics, Peptides, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of tecemotide in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Started Oct 2014; status: suspended.
02
Drugs
tecemotide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20132488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132488.